These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34487055)

  • 1. Compassionate drug use for patients with transthyretin amyloid cardiomyopathy.
    Ciliberti G; Urbinati A; Barbarossa A; Stronati G; Silenzi M; Principi S; Falanga U; Capucci A; Casella M; Dello Russo A; Guerra F
    J Cardiovasc Med (Hagerstown); 2021 Oct; 22(10):792-794. PubMed ID: 34487055
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
    Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
    ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
    Witteles RM; Bokhari S; Damy T; Elliott PM; Falk RH; Fine NM; Gospodinova M; Obici L; Rapezzi C; Garcia-Pavia P
    JACC Heart Fail; 2019 Aug; 7(8):709-716. PubMed ID: 31302046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel drugs targeting transthyretin amyloidosis.
    Hanna M
    Curr Heart Fail Rep; 2014 Mar; 11(1):50-7. PubMed ID: 24464360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac amyloidosis with gastrointestinal involvement: a case report.
    Tantau A; Avram I; Cozma A; Sampelean D
    Med Ultrason; 2015 Mar; 17(1):123-5. PubMed ID: 25745667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tafamidis for the treatment of transthyretin amyloidosis.
    Lorenzini M; Elliott PM
    Future Cardiol; 2019 Mar; 15(2):53-61. PubMed ID: 30767672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From hypertrophic cardiomyopathy to transthyretin amyloidosis: an unusual case and challenging diagnosis.
    Petkow-Dimitrow P; Rajtar-Salwa R; Holcman K; Kostkiewicz M; Rubiś P
    Pol Arch Intern Med; 2020 Feb; 130(2):153-154. PubMed ID: 31933485
    [No Abstract]   [Full Text] [Related]  

  • 9. Redefining Prognosis of Transthyretin Cardiomyopathy in the Tafamidis Era.
    Zaghlol R; Rater M; Schiffer W; Mitchell JD
    J Card Fail; 2022 Oct; 28(10):1519-1521. PubMed ID: 35988721
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnosis of cardiac transthyretin amyloidosis based on multimodality imaging.
    Dahlem K; Michels G; Kobe C; Bunck AC; Ten Freyhaus H; Pfister R
    Clin Res Cardiol; 2017 Jun; 106(6):471-473. PubMed ID: 28303323
    [No Abstract]   [Full Text] [Related]  

  • 11. Sporadic transthyretin amyloidosis with a novel TTR gene mutation misdiagnosed as primary amyloidosis.
    Briani C; Cavallaro T; Ferrari S; Taioli F; Calamelli S; Verga L; Adami F; Fabrizi GM
    J Neurol; 2012 Oct; 259(10):2226-8. PubMed ID: 22580845
    [No Abstract]   [Full Text] [Related]  

  • 12. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
    Maurer MS; Schwartz JH; Gundapaneni B; Elliott PM; Merlini G; Waddington-Cruz M; Kristen AV; Grogan M; Witteles R; Damy T; Drachman BM; Shah SJ; Hanna M; Judge DP; Barsdorf AI; Huber P; Patterson TA; Riley S; Schumacher J; Stewart M; Sultan MB; Rapezzi C;
    N Engl J Med; 2018 Sep; 379(11):1007-1016. PubMed ID: 30145929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
    Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
    Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful use of palliative inotrope therapy in end-stage cardiac ATTR amyloidosis.
    Panhwar MS; Al-Kindi S; Oliveira GH; Ginwalla M
    Amyloid; 2017 Dec; 24(4):217-218. PubMed ID: 28868918
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world versus trial patients with transthyretin amyloid cardiomyopathy.
    Canepa M; Tini G; Musumeci B; Cappelli F; Milandri A; Mussinelli R; Autore C; Perfetto F; Rapezzi C; Perlini S
    Eur J Heart Fail; 2019 Nov; 21(11):1479-1481. PubMed ID: 31339212
    [No Abstract]   [Full Text] [Related]  

  • 16. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
    Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
    Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transthyretin amyloidosis in a septuagenarian masquerading as hypertrophic cardiomyopathy: the importance of multimodality imaging.
    Chawla D; Cheema O; Jan MF; Tajik AJ
    Eur Heart J Cardiovasc Imaging; 2018 Mar; 19(3):328. PubMed ID: 29272373
    [No Abstract]   [Full Text] [Related]  

  • 18. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
    Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?
    Falk RH
    Eur Heart J; 2019 Mar; 40(12):1009-1012. PubMed ID: 30668704
    [No Abstract]   [Full Text] [Related]  

  • 20. Indications and diagnostic yield of endomyocardial biopsies for unexplained cardiomyopathy, a single center experience.
    Ramaekers J; Janssens J; Waumans L; Stessens L; Dupont M; Mullens W; Martens P
    Acta Cardiol; 2020 Apr; 75(2):138-146. PubMed ID: 30650043
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.